Business Description
Compare
Compare
Traded in other countries / regions
543635.India IPO Date
2022-10-19Description
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.11 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.6 | |||||
| Debt-to-EBITDA | 3.3 | |||||
| Interest Coverage | 1.13 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.12 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 38.4 | |||||
| 3-Year EBITDA Growth Rate | 27.6 | |||||
| 3-Year EPS without NRI Growth Rate | -58.6 | |||||
| 3-Year Book Growth Rate | 21.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 183.07 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.52 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.02 | |||||
| 9-Day RSI | 54.69 | |||||
| 14-Day RSI | 58.65 | |||||
| 6-1 Month Momentum % | 51.04 | |||||
| 12-1 Month Momentum % | 90.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | |||||
| Quick Ratio | 0.75 | |||||
| Cash Ratio | 0.12 | |||||
| Days Inventory | 217.76 | |||||
| Days Sales Outstanding | 83.13 | |||||
| Days Payable | 154.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.05 | |||||
| Forward Dividend Yield % | 0.05 | |||||
| 5-Year Yield-on-Cost % | 0.05 | |||||
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | 2.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.21 | |||||
| Operating Margin % | 5.93 | |||||
| Net Margin % | 0.33 | |||||
| FCF Margin % | 3.52 | |||||
| ROE % | 0.37 | |||||
| ROA % | 0.19 | |||||
| ROIC % | 0.44 | |||||
| 3-Year ROIIC % | -4.08 | |||||
| ROC (Joel Greenblatt) % | 9.5 | |||||
| ROCE % | 6.19 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 892.4 | |||||
| Forward PE Ratio | 106.97 | |||||
| PE Ratio without NRI | 508.2 | |||||
| PS Ratio | 3.48 | |||||
| PB Ratio | 3.72 | |||||
| Price-to-Tangible-Book | 8.12 | |||||
| Price-to-Free-Cash-Flow | 97.9 | |||||
| Price-to-Operating-Cash-Flow | 28.51 | |||||
| EV-to-EBIT | 49.76 | |||||
| EV-to-EBITDA | 23.58 | |||||
| EV-to-Revenue | 4.05 | |||||
| EV-to-FCF | 113.36 | |||||
| Price-to-Graham-Number | 16.4 | |||||
| Earnings Yield (Greenblatt) % | 2.01 | |||||
| FCF Yield % | 0.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Piramal Pharma Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 83,087 | ||
| EPS (TTM) (₹) | 0.25 | ||
| Beta | 0 | ||
| Volatility % | 26.8 | ||
| 14-Day RSI | 58.65 | ||
| 14-Day ATR (₹) | 9.221475 | ||
| 20-Day SMA (₹) | 221.7375 | ||
| 12-1 Month Momentum % | 90.81 | ||
| 52-Week Range (₹) | 87.55 - 244.1 | ||
| Shares Outstanding (Mil) | 1,320.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Piramal Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Piramal Pharma Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Piramal Pharma Ltd Frequently Asked Questions
What is Piramal Pharma Ltd(BOM:543635)'s stock price today?
The current price of BOM:543635 is ₹223.10. The 52 week high of BOM:543635 is ₹244.10 and 52 week low is ₹87.55.
When is next earnings date of Piramal Pharma Ltd(BOM:543635)?
The next earnings date of Piramal Pharma Ltd(BOM:543635) is .
Does Piramal Pharma Ltd(BOM:543635) pay dividends? If so, how much?
The Dividend Yield %  of Piramal Pharma Ltd(BOM:543635) is 0.05% (As of Today), Highest Dividend Payout Ratio of Piramal Pharma Ltd(BOM:543635) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Piramal Pharma Ltd(BOM:543635) is 0.05%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers